title: Intacs implantation with sequential collagen cross-linking treatment in postoperative LASIK ectasia.
abstract: OBJECTIVE
  To report the postoperative course and refractive results of each eye of a patient with postoperative LASIK ectasia for whom Intacs SK (severe keratoconus, Addition Technology Inc) implantation and collagen crosslinking (CXL) treatments were performed.
  
  
  METHODS
  A 27-year-old man with postoperative LASIK ectasia with best spectacle-corrected visual acuity (BSCVA) of 20/60 and 20/80 in the right and left eyes, respectively, was operated for Intacs SK implantation for both eyes. Spherical equivalent refraction and mean keratometric values in the right and left eyes were -14.50 diopters (D) and -10.50 D and 56.20 D and 50.70 D, respectively. Following bilateral Intacs SK implantation, CXL was performed after 1 day in the left eye and 1 month in the right eye.
  
  
  RESULTS
  During follow up, there was an improvement in visual acuity and decrease in manifest refraction and keratometric values in both eyes. A slight regression of these values was noted in the right eye 1 month after Intacs SK implantation, which was reversed by CXL. Eight months postoperatively, BSCVA was 20/25 and 20/25, manifest refractions were -1.50 x 170 and -1.25 x 50, and mean keratometric values were 47.20 and 44.20 D in the right and left eyes, respectively.
  
  
  CONCLUSIONS
  Intacs SK implantation and subsequent CXL may be alternatived in the treatment of postoperative LASIK ectasia.
authors.affiliation: Kudret Eye Hospital, Kennedy Caddesi No: 71, Kavaklidere, Ankara, Turkey 06670. gunhal@gmail.com
authors.forename: Günhal
authors.initials: G
authors.lastname: Kamburoglu
authors.forename: Aylin
authors.initials: A
authors.lastname: Ertan
mesh_terms: D000328:Adult; D003094:Collagen / Q000378:metabolism*; D003131:Combined Modality Therapy; D003315:Cornea / Q000187:drug effects / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects / Q000601:surgery; D003316:Corneal Diseases / Q000188:drug therapy / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D003319:Corneal Stroma / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D019781:Corneal Topography; D004108:Dilatation, Pathologic / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D006801:Humans; D020731:Keratomileusis, Laser In Situ; D008297:Male; D009216:Myopia / Q000601:surgery; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D019904:Polymethyl Methacrylate; D011183:Postoperative Complications; D019736:Prostheses and Implants; D019919:Prosthesis Implantation; D012256:Riboflavin / Q000627:therapeutic use; D014466:Ultraviolet Rays; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D003094:Collagen; D019904:Polymethyl Methacrylate; D012256:Riboflavin